EHRA score three (OR 18.7; 95 CI 3.82.1;PB1081|Accounting of Symptoms and Ejection Fraction May well Boost Prediction of Left Atrial Thrombus in Individuals with Nonvalvular Atrial Fibrillation ahead of Catheter Ablation or Cardioversion I. Zaigraev; I. Yavelov; O. Drapkina; E. Bazaeva National Healthcare Analysis Bak Activator Molecular Weight Center for Therapy and Preventive Medicine on the Ministry of Overall health of your Russian Federation, Moscow, Russian Federation Background: Optimal method for prediction of left atrial thrombus (LAT) in sufferers with nonvalvular atrial fibrillation (NAF) isn’t established yet. Aims: To evaluate possibilities for prediction of LAT before catheter ablation or cardioversion in patients with NAF. Approaches: Within a retrospective single-center study medical records of 1994 patients with NAF underwent transesophagealP 0.0001), left ventricular ejection fraction [EF] (OR 0.89; 95 CI 0.81.98; P = 0.017) and CHA 2DS2-VASc-RAF score (OR 1.24; 95 CI 1.04.50, P = 0.017) were connected with LAT. Addition of EHRA score three (+11 points) and EF 48 (+6 points) to CHA2DS2-VAScRAF score increased C-statistics from 0.83 (95 CI 0.76.91) to 0.87 (95 CI 0.80.94). Optimal cut-off for modified CHA2DS2-VAScRAF score was 8 points (OR 25.eight; 95 CI 5.912.3, P 0.0001). Sensitivity, specificity, good and negative predictive values of CHA 2DS2-VASc-RAF and modified CHA 2DS2-VASc-RAF scores are presented inside the table 1 Conclusions: Accounting of severity of symptoms and reduced EF may slightly raise predictive value of CHA 2DS2-VASc-RAF score for left atrial thrombus in individuals with non-valvular AF just before catheter ablation or cardioversion.TABLE 1 Predictive values of CHA2DS2-VASc-RAF and modified CHA2DS2-VASc-RAF scores for LAT in sufferers with NAF prior to catheter ablation or cardioversionHigh values of danger scores Sensitivity 90,six 93,five Specificity 57,1 , 64,0 PPV 30,two 34,9 NPV 96,7 97,9CHA 2DS2-VASc-RAF 3 pointsModified CHA 2DS2-VASc-RAF eight pointsPPV good predictive worth; NPV damaging predictive value.PB1082|Inappropriate Direct Oral Anticoagulant Dosing within a Spanish Cohort with Atrial Fibrillation B. Navarro Almenzar1; J.J. Cerezo Manchado2; F. Garc Candel1Methods: Retrospective study that incorporated patients with AF who began a DOAC (Rivaroxaban, Apixaban, Dabigatran or Edoxaban) from January 1, 2013 to December 31, 2016, in 3 Spanish hospitals (Hospital Cl ico Universitario Virgen de la Arrixaca, Hospital Comarcal del Noroeste and Hospital Vega Baja). Inappropriate dosing was analysed based on labeling recommendations. Thromboembolic, hemorrhagic complications and mortality have been recorded. Mean follow-up was 1,six years. Statistical evaluation was performed using SPSSStatistics program v25 (SPSS Inc., Chicago, Illinois, USA). Outcomes: A total of 2218 patients had been included, of which, 506 individuals (23 ) have been receiving an inappropriate dose. Amongst these patients, inappropriate lowered dose (underdosing) predominated (87 ). Table 1 shows the primary qualities in the cohort. Rivaroxaban was the drug incorrectly prescribed most often.Hospital General Universitario Rafael M dez, Murcia, Spain; Hospital Common Universitario Santa Luc , Murcia, Spain; HospitalCl ico Universitario Virgen de la Arrixaca, Murcia, Spain Background: Atrial fibrillation (AF) will be the most prevalent arrhythmia worldwide, becoming the principle cause of DYRK2 Inhibitor Formulation anticoagulation. DOACS are utilized frequently for the stroke prevention in these individuals. Every single DOAC has two presentations, the typical dos
